 |
|
|||||
| Day One | Day Two | |||||
| Cyprotex Introduction to ADME Training Course September 22nd, 2010. 1.00pm - 5.00pm |
6th North American Drug Discovery Workshop September 23rd, 2010. 8.00am - 5.30pm |
|||||
| Free registration RSVP before September 17th, 2010 |
 |
Free registration RSVP before September 17th, 2010 |
|
|||
 |
|
|||||
 |
||
| Day One. ADME Training Course | ||
|
||
| Clive Dilworth Director of Scientific Operations (UK), Cyprotex |
||
|
||
| Michael Griffin Senior Principal Scientist, Cyprotex |
||
|
||
| Day Two. Drug Discovery Workshop | ||
|
||
| Edward Kerns Consultant, Discovery ADME |
||
| Integrating in vitro and in vivo DMPK studies to guide structure optimization in drug discovery | ||
|
||
| Konstantine Skordos Section Manager, DMPK, GSK |
||
| Reducing late stage attrition: Predicting hepatotoxicity in the clinic from early preclinical screening data | ||
|
||
| Rod Cole Associate Director, Drug Metabolism and Pharmacokinetics, Abbott Bioresearch Center |
||
| Bioanalytical technologies for early DMPK discovery support: Practical considerations and applications |
||
|
||
| Norman Huebert Team Leader & Research Fellow ADME, Johnson & Johnson |
||
| Research strategies in LG and LO: Combining in vitro and in vivo ADME approaches | ||
|
||
| Bernard Murray Senior Research Scientist I, Gilead |
||
| Targeted solutions to DMPK problems: Avoiding unnecessary screening | ||
|
||
| Peng Hsiao Research Assistant, Jashvant D Unadkat Lab, University of Washington |
||
| P-gp based drug interactions at the blood-brain barrier: Fact or fantasy? | ||
|
||
| Simon Thomas Head of Scientific Computing, Cyprotex |
||
| Physiologically based pharmacokinetic/pharmacodynamic modelling for lead optimisation of CNS-Active therapeutics | ||
|
||
| Katya Tsaioun Chief Scientific Officer, Cyprotex |
||
| New technologies for mechanistic toxicology in lead de-risking: CellCiphr™ Cellular Systems Biology (CSB™) approach | ||
